House-passed opioid abatement bill (H 218) draws committee scrutiny over appropriations and governance

Senate Health & Welfare members examined H 218, the house-passed bill that centralizes opioid abatement appropriations into a single bill and adds policy changes for how the special fund is governed and monitored.

Teresa Wood, chair of House Human Services and a presenter on the bill, told the committee that Human Services worked to align the recommendations of the opioid abatement advisory committee and the Department of Health: “House Human Services really took great pains ... to avoid deviating from the recommendations of the opioid advisory settlement committee.” The administration asked that the special-fund appropriations be consolidated into a single bill for clarity.

Nolan (fiscal office) walked the committee through the fiscal note: the house version of H 218 appropriates roughly $9.8–$9.9 million for fiscal year 2026, and includes several line items earmarked for ongoing grants and programs. Nolan noted that previous appropriations from earlier acts have left unspent balances in some awards and that the committee should be aware of money already allocated but not yet spent.

Katie McGlennox, legislative counsel, summarized the bill’s policy changes. Key edits require grant agreements to collect outcomes and measurements reported back to the issuing department and to the settlement advisory committee; the advisory committee must cross-reference proposed recommendations to the statutory authorized uses of the special fund; and the advisory committee shall elect a voting vice chair from among its non-governmental members (the chair remains a non-voting member). The bill also updates statutory terminology, replacing references to “medication-assisted treatment (MAT)” with “medication for opioid use disorder (MOUD)” across the statute.

Committee members pressed on program readiness and prior-year spending for several grants funded from the settlement. Some members asked why recipients had not yet expended prior awards before requesting additional funds. David Mickenberg, speaking about the Burlington overdose prevention center (OPC), said his city council had held a working session and that the city had hired staff, selected a provider through an RFP and planned careful site selection and community engagement. “They plan on using that money in FY '25, at least as much as they can, and then beyond,” Mickenberg said, describing Burlington’s timeline to stand up operations and address safety and neighborhood concerns.

Members discussed the long-term revenue outlook for the opioid fund and cautioned that settlement receipts will decline over time unless additional settlements (for example, Sackler-related bankruptcy proceeds) materially change the revenue picture. Nolan shared a projection chart in which inflows to the fund hover in the $4–5 million range in coming years and then decline after the peak years; the committee was told that the more the Legislature spends now out of one-time settlement receipts, the less will be available in future years.

Next steps: committee staff indicated H 218 could be taken up for a committee decision at the follow-up meeting; members requested additional documentation on unspent prior awards and more detail from Burlington on OPC readiness before final action.

Ending: H 218 remains before the committee for a possible motion at the next session; members emphasized both the need for outcome measurement and prudence about multi-year obligations from one-time or declining settlement receipts.